Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Intravenous Ferric Carboxymaltose on Reverse Remodeling Following Cardiac Resynchronization Therapy
2017-001623-44Phase 4Completed
- Sponsor
- Ziekenhuis Oost-Limburg
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in heart failure with reduced ejection fraction (HFrEF) and heart failure (HF) comparing Ferric carboxymaltose with Placebo (2 arms). Primary endpoint: Change in left ventricular ejection fraction. Started May 2017; status: completed.
02
Drugs
ferric carboxymaltose
03
Conditions
heart failure with reduced ejection fraction (HFrEF)heart failure (HF)
Beyond the preview
Go deeper on 2017-001623-44.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001623-44.